TY - JOUR T1 - Photodynamic Therapy Using Talaporfin Sodium (Laserphyrin®) for Bile Duct Carcinoma: A Preliminary Clinical Trial JF - Anticancer Research JO - Anticancer Res SP - 4931 LP - 4938 VL - 32 IS - 11 AU - ATSUSHI NANASHIMA AU - TAKAFUMI ABO AU - TAKASHI NONAKA AU - YOSHIKAZU NONAKA AU - TOMOHITO MORISAKI AU - RYOUHEI UEHARA AU - KEN OHNITA AU - DAISUKE FUKUDA AU - GOSHI MURAKAMI AU - KAZUO TOU AU - MASAKI KUNIZAKI AU - SHIGEKAZU HIDAKA AU - TOMOSHI TSUCHIYA AU - HIROAKI TAKESHITA AU - KAZUHIKO NAKAO AU - TAKESHI NAGAYASU Y1 - 2012/11/01 UR - http://ar.iiarjournals.org/content/32/11/4931.abstract N2 - The efficacy of adjuvant photodynamic therapy (PDT) using the new photosensitizer, talaporfin sodium (TPS), was assessed in 7 patients with bile duct carcinoma (BDC). The 664-nm semiconductor laser (100 J/cm2) was applied through endoscopy to the tumor lesion within 6 h after injection of TPS. Cases included three non-resectable and 4 resected BDC with remnant cancer cells at the bile duct stump. Radiated lesions exhibited mild inflammatory responses. Locally advanced tumor occluding bile duct was relieved by PDT and patency was maintained for 16 months. Two patients developed mild photodermatitis but no severe morbidity. One patient died of other disease, and two patients died of liver metastasis within 6 months, but local recurrence was not observed. Three patients maintained cancer-free survival for 6-13 months. One patient survived with good status for 24 months. Adjuvant TPS-PDT is a safe and useful treatment for local control of BDC. Compared to the conventional PDT, the patient's quality of life is remarkably improved. ER -